SCHEMBL3948845

SCHEMBL3948845

O=C(O)C1Cc2ccccc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.56
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.54
ACHE P22303 4/20 0.53
METAP1 P53582 4/20 0.45
LMNA P02545 1/20 0.43
RAB9A P51151 1/20 0.43
EDNRB P24530 1/20 0.42
EDNRA P25101 1/20 0.42
CYP19A1 P11511 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30702212 1.00 MAPT (0.56) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL23618751 0.85 MAPT (0.70) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL3886865 0.84 SMN1; SMN2 (0.47) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL5311960 0.83 KMT2A (0.55) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL856747 0.83 ACHE (0.56) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL8021509 0.81 ACHE (0.54) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL13637485 0.80 KDM4E (0.52) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL28234149 0.80 RAB9A (0.61) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL19836626 0.79 ALDH1A1 (0.54) MAPTKDM4EMEN1KMT2AL3MBTL1
SCHEMBL24193320 0.79 PTGS2 (0.47) MAPTKDM4EMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115746222-A Composite water reducing agent and preparation process thereof 广东六合新型建材有限公司 2023-03-07 CN claimed
US-11874601-B2 Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent TOKYO OHKA KOGYO CO., LTD. (JP) 2024-01-16 US disclosed
US-11874601-B2 Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent TOKYO OHKA KOGYO CO., LTD. (JP) 2024-01-16 US disclosed
CN-115746222-A Composite water reducing agent and preparation process thereof 广东六合新型建材有限公司 2023-03-07 CN disclosed
CN-113121338-B Synthetic method of alpha-hydroxy-beta-keto acid ester compound 浙江工业大学 2022-10-28 CN disclosed
CN-114539055-A Method for realizing phase transfer catalysis beta-dicarbonyl compound alkylation reaction by using microchannel reactor 西安近代化学研究所 2022-05-27 CN disclosed
CN-110372507-B Novel method for preparing chiral alpha-hydroxy-beta-dicarbonyl compound by photocatalytic asymmetric oxidation 大连理工大学 2022-04-15 CN disclosed
CN-110372506-B Novel method for realizing visible light catalytic asymmetric oxidation by utilizing microreactor 大连理工大学 2022-04-15 CN disclosed
CN-110872232-B Method for phase transfer catalysis of beta-keto ester asymmetric alpha-difluoromethylation 新乡医学院 2022-01-25 CN disclosed
US-20220011665-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT TOKYO OHKA KOGYO CO., LTD. (JP) 2022-01-13 US disclosed
US-6313120-B1 TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS SANOFI-SYNTHELABO (FR) 2001-11-06 US disclosed
CN-1268937-A Novel compound having effect of promoting neuron differentiation NIPPON KAYAKU KK (JP) 2000-10-04 CN disclosed
US-6100278-A COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS SANOFI-SYNTHELABO (FR) 2000-08-08 US disclosed
EP-0991772-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS Biocatalytics, Inc. (US) 2000-04-12 EP disclosed
US-6015812-A N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity SANOFI-SYNTHELABO (FR) 2000-01-18 US disclosed
US-5942644-A Precursors for the production of chiral vicinal aminoalcohols BIOCATALYTICS, INC. (US) 1999-08-24 US disclosed
WO-1998054350-A1 METHODS AND PRECURSORS FOR THE PRODUCTION OF CHIRAL VICINAL AMINOALCOHOLS BIOCATALYTICS, INC. (US) 1998-12-03 WO disclosed
EP-0699069-A4 1996-04-03 EP disclosed
EP-0699069-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-03-06 EP disclosed
WO-1994025013-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220011665-A1 RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND, AND ACID DIFFUSION-CONTROLLING AGENT MRPS23, MRPS22, SLC11A2 MAPT 4785/4885KDM4E 3259/4885MEN1 1123/4885
US-11874601-B2 Resist composition, method of forming resist pattern, compound, and acid diffusion-controlling agent MRPS23, MRPS22, SLC11A2 MAPT 4792/4885KDM4E 3127/4885MEN1 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.